By SmashMeals Editorial — 2026-10-01 — Health & Nutrition
The short answer
MariTide (maridebart cafraglutide) is an investigational obesity medicine designed for less-frequent dosing than current weekly injections. Phase 2 data studied monthly dosing, and Phase 3 development is underway. There is not yet an approved MariTide meal-timing or nutrition protocol.
Key facts
- MariTide is also known as maridebart cafraglutide.
- It combines GLP-1 receptor agonism with GIP receptor antagonism.
- Phase 2 research evaluated monthly dosing.
- Amgen has moved MariTide into Phase 3 development.
- MariTide remains investigational and does not have an FDA-approved food or dosing label.
KINGSPORT, Tenn., Oct. 1, 2026 — Weekly injections have defined much of the modern obesity-drug market. MariTide is testing a different proposition: much less frequent dosing. Amgen's investigational medicine, also called maridebart cafraglutide, has been studied with monthly administration and is now in Phase 3 development.
MariTide is investigational. There is no approved MariTide diet or consumer dosing protocol.
A different mechanism and a different schedule
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism. Its long-acting design is intended to support dosing intervals longer than the weekly schedule familiar from semaglutide and tirzepatide.
Why meal timing could become a research question
With weekly medicines, some patients report that appetite and gastrointestinal tolerance vary across the week, although experiences differ. A monthly therapy raises the question of whether food intake or tolerance might follow a different pattern across a longer interval. The answer requires data; it should not be guessed from another medication.
What shoppers can do now
People using currently approved obesity medicines can keep meal planning flexible: visible nutrition information, portions that can be adjusted, and food available when appetite permits. Our GLP-1 nutrition hub covers approved therapies; our peptide research guide separates those from investigational candidates.
Commentary, not medical advice
The SmashMeals perspective
MariTide raises a genuinely new food question: if obesity treatment eventually moves from weekly to monthly or less-frequent dosing, will appetite and food tolerance vary differently across the dosing interval? That is worth studying. It is not something a meal company should answer before clinical data do.
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.
- Maridebart Cafraglutide for the Treatment of Obesity — New England Journal of Medicine
Why it matters: Primary peer-reviewed Phase 2 clinical trial. - MariTide demonstrates substantial and sustained weight loss — Amgen
Why it matters: Developer summary of Phase 2 results and development direction.